Healius Limited (AU:HLS)
ASX:HLS
Top Page
Healius Limited
(Sydney:HLS)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.53
▼(-2.04% Downside)
Action:ReiteratedDate:02/25/26
Overall score reflects weak financial performance (declining revenue, negative margins, high leverage) and bearish technicals (below all major moving averages with negative MACD). Valuation signals are also impaired due to negative earnings (negative P/E) with no dividend yield data to offset risk.
Positive Factors
Positive operating cash flow
Healius's positive operating cash flow provides durable liquidity to fund day-to-day operations and absorb near-term losses. Sustained OCF supports working capital, allows management to prioritize restructuring or efficiency programs, and reduces immediate refinancing pressure over the medium term.
Negative Factors
Revenue decline
A 13.8% revenue decline signals material structural challenges such as lost volumes, weaker referrals, or pricing pressure. Sustained top-line contraction undermines fixed-cost absorption in labs and imaging, forcing longer-term margin compression and requiring strategic actions to restore scale and utilisation.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive operating cash flow
Healius's positive operating cash flow provides durable liquidity to fund day-to-day operations and absorb near-term losses. Sustained OCF supports working capital, allows management to prioritize restructuring or efficiency programs, and reduces immediate refinancing pressure over the medium term.
Read all positive factors
Healius Limited (HLS) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$392.11M
Dividend YieldN/A
Average Volume (3M)2.94M
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue Growth-23.02%
EPS Growth33.11%
CountryAU
Employees4,329
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding726,132,800
10 Day Avg. Volume3,249,015
30 Day Avg. Volume2,941,962
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.26
Price to Sales (P/S)0.11
P/FCF Ratio0.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.74Price Target Upside37.62% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering6
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$1.40B
Healius Limited Business Overview & Revenue Model
Company Description
Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through four segments: Pathology, Imaging, Day Hospitals, and Others. It offers diagnostic imaging services, private medical la...
How the Company Makes Money
Healius primarily makes money by delivering diagnostic services and earning fees for each test or scan performed. Its key revenue streams are (1) Pathology: revenue is generated when patient specimens are collected (via collection centres and othe...
Healius Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
50
Neutral
Cash Flow
55
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.37B | 1.34B | 1.75B | 1.71B | 2.29B | 1.90B |
| Gross Profit | 331.90M | 398.60M | 1.52B | 341.70M | 779.20M | 526.50M |
| EBITDA | 206.80M | 31.20M | -298.10M | -57.80M | 734.80M | 470.40M |
| Net Income | -168.80M | -151.20M | -645.80M | -367.80M | 307.90M | 43.70M |
Balance Sheet | ||||||
| Total Assets | 1.77B | 1.78B | 2.98B | 3.65B | 4.14B | 3.78B |
| Cash, Cash Equivalents and Short-Term Investments | 51.60M | 57.20M | 60.10M | 115.30M | 81.30M | 70.10M |
| Total Debt | 1.66B | 911.80M | 1.60B | 1.77B | 1.78B | 1.44B |
| Total Liabilities | 1.22B | 1.19B | 1.94B | 2.15B | 2.22B | 1.92B |
| Stockholders Equity | 557.10M | 587.90M | 1.04B | 1.51B | 1.92B | 1.86B |
Cash Flow | ||||||
| Free Cash Flow | 124.30M | 231.70M | 173.80M | 230.30M | 480.30M | 432.00M |
| Operating Cash Flow | 174.70M | 285.70M | 266.80M | 306.40M | 573.80M | 493.30M |
| Investing Cash Flow | 734.50M | 730.00M | -63.00M | 67.30M | -401.70M | 386.90M |
| Financing Cash Flow | -973.90M | -1.02B | -259.00M | -339.70M | -163.50M | -984.70M |
Healius Limited Technical Analysis
Negative
0.54
Price Trends
0.77
Negative
0.85
Negative
0.82
Negative
Market Momentum
-0.06
Negative
20.53
Positive
10.91
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HLS, the sentiment is Negative. The current price of 0.54 is below the 20-day moving average (MA) of 0.62, below the 50-day MA of 0.77, and below the 200-day MA of 0.82, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 20.53 is Positive, neither overbought nor oversold. The STOCH value of 10.91 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HLS.
Healius Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | AU$9.71B | 10.64 | 6.39% | 4.69% | 9.44% | -0.37% | |
67 Neutral | AU$253.26M | 10.00 | 6.06% | 6.22% | 6.65% | ― | |
59 Neutral | AU$370.93M | 23.92 | 16.35% | 4.60% | 6.73% | 37.16% | |
55 Neutral | AU$905.69M | 26.42 | 2.05% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | AU$392.11M | -5.40 | -67.21% | ― | -23.02% | 33.11% | |
41 Neutral | AU$17.26M | -2.23 | -23.93% | ― | 62.81% | 16.37% |
* Healthcare Sector Average
AU:HLS
Healius Limited
0.58
-0.49
-45.81%
AU:GSS
Genetic Signatures Ltd.
0.09
-0.41
-82.20%
AU:SHL
Sonic Healthcare Limited
20.15
-4.70
-18.90%
AU:IDX
Integral Diagnostics Ltd.
2.36
0.09
4.10%
AU:ACL
Australian Clinical Labs Ltd
2.02
-0.83
-29.22%
AU:MVF
Monash IVF Group Ltd
0.65
-0.44
-40.37%
Healius Limited Corporate Events
Healius Director Katherine Ostin Increases Indirect Shareholding
Mar 13, 2026
Healius Limited has disclosed a change in director Katherine Ostin’s interests in the company’s securities, following an on‑market purchase of additional fully paid ordinary shares. Ostin’s indirect holding, through Nitso P...
Healius Director Steven Rubic Increases Shareholding via On-Market Purchase
Mar 12, 2026
Healius Limited has disclosed a change in the shareholding of director Steven Rubic, who increased his direct holding in the company through on-market trades. Rubic acquired 130,000 fully paid ordinary shares at an average price of $0.595 per shar...
Healius director Katherine Ostin increases shareholding via on-market trades
Mar 10, 2026
Healius has disclosed a change in the interests of non-executive director Katherine Ostin, following on-market purchases of additional fully paid ordinary shares in the company. Ostin acquired 16,264 shares at an average price of $0.6148 per share...
Healius Director Katherine Ostin Lifts Indirect Shareholding in On‑Market Trades
Mar 5, 2026
Healius Limited has disclosed a change in the securities held by non‑executive director Katherine Ostin, detailing updated direct and indirect interests in the company’s fully paid ordinary shares. The filing notes that Ostin’s i...
Healius Appoints Bruce Robinson to Board With No Current Shareholding
Feb 2, 2026
Healius Limited has announced the appointment of Bruce Robinson as a director of the company, effective 2 February 2026. According to the initial director’s interest notice lodged with the ASX, Robinson currently holds no relevant interests ...
Healius Sets Date and Webcast Details for 1H26 Results Briefing
Jan 27, 2026
Healius Limited has announced that it will release its financial results for the first half of the 2026 financial year on 18 February 2026, followed by a webcast briefing for analysts and investors. The company will host an online presentation at ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.